Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo

Cancer Science

Volumn 103, Issue 2, 2012, Pages 228-232

  Nishioka, Nobuaki ^a   Matsuoka, Tasuku ^a   Yashiro, Masakazu ^b   Hirakawa, Kosei ^b   Olden, Kenneth ^a   Roberts, John D ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMID VECTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADENOVIRUS INFECTION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; CANCER GROWTH; CANCER INHIBITION; CANCER SURGERY; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; STOMACH CANCER; TUMOR GROWTH;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; HUMANS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PLASMIDS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA INTERFERENCE; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TRANSFECTION;

EID: 84856509499     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02155.x     Document Type: Article

References (31)

1. Sawyer TK. Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. Expert Opin Investig Drugs 2004; 13: 1-19.
2. Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med 2004; 128: 765-70.
3. Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M. Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as "soil" for peritoneal dissemination. Cancer 1996; 77: 1668-75.
4. Kaibara N, Maeta M, Hamazoe R, Inoue Y, Koga S. Hyperthermia adjunct to surgery in the treatment of scirrhous carcinoma of the stomach. Gan To Kagaku Ryoho 1988; 15: 1269-72 (in Japanese).
5. Soff GA, Sanderowitz J, Gately S et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 1995; 96: 2593-600.
6. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57: 25-40.
7. Czekay RP, Wilkins-Port CE, Higgins SP et al. PAI-1: an integrator of cell signaling and migration. Int J Cell Biol 2011; 2011: 562481.
8. Quax PH, van Muijen GN, Weening-Verhoeff EJ et al. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J Cell Biol 1991; 115: 191-9.
9. Tsuchiya H, Sunayama C, Okada G, Matsuda E, Tomita K, Binder BR. Plasminogen activator inhibitor-1 accelerates lung metastasis formation of human fibrosarcoma cells. Anticancer Res 1997; 17: 313-6.
10. Whitley BR, Palmieri D, Twerdi CD, Church FC. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Exp Cell Res 2004; 296: 151-62.
11. Morita Y, Hayashi Y, Kanamaru T et al. Inhibitory role of plasminogen activator inhibitor-1 in invasion and proliferation of HLE hepatocellular carcinoma cells. Jpn J Cancer Res 1999; 90: 747-52.
12. Bajou K, Maillard C, Jost M et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 2004; 23: 6986-90.
13. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000; 404: 293-6.
14. Stein P, Svoboda P, Schultz RM. Transgenic RNAi in mouse oocytes: a simple and fast approach to study gene function. Dev Biol 2003; 256: 187-93.
15. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2: 243-7.
16. Sumimoto H, Miyagishi M, Miyoshi H et al. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 2004; 23: 6031-9.
17. Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M. Establishment of two new scirrhous gastric cancer cell lines: analysis of factors associated with disseminated metastasis. Br J Cancer 1995; 72: 1200-10.
18. Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M. Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice. Clin Exp Metastasis 1996; 14: 43-54.
19. Nishioka N, Matsuoka T, Yashiro M, Hirakawa K, Olden K, Roberts JD. Linoleic acid enhances angiogenesis through suppression of angiostatin induced by plasminogen activator inhibitor 1. Br J Cancer 2011; 105: 1750-8.
20. Bell WR. The fibrinolytic system in neoplasia. Semin Thromb Hemost 1996; 22: 459-78.
21. Wohrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol 2004; 15: 1585-95.
22. Lacave AJ, Baron FJ, Anton LM et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol 1991; 2: 751-4.
23. Rougier P, Ducreux M, Mahjoubi M et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 1994; 30A: 1263-9.
24. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19: 3447-55.
25. Gutheil JC, Campbell TN, Pierce PR et al. Targeted antiangiogenic therapy for cancer using vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000; 6: 3056-61.
26. Mulcahy MF, Benson AB 3rd. Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 2005; 5: 997-1005.
27. Ugurel S, Hildenbrand R, Zimpfer A et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005; 92: 1398-405.
28. Durand MK, Bodker JS, Christensen A et al. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost 2004; 91: 438-49.
29. Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997; 90: 204-8.
30. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
31. Beerepoot LV, Witteveen EO, Groenewegen G et al. Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study. Clin Cancer Res 2003; 9: 4025-33.